INTEGRA LIFESCIENCES HOLDINGS CORP 8-K

What Happened

• Integra LifeSciences Holdings Corporation (IART) filed an 8-K on May 8, 2026 reporting results from its May 7, 2026 Annual Meeting. Stockholders approved Amendment No. 3 to the Company’s Fifth Amended and Restated 2003 Equity Incentive Plan to increase the pool by 3,550,000 shares.
• All seven director nominees were elected to serve until the 2027 annual meeting. PricewaterhouseCoopers LLP was ratified as the Company’s independent registered public accounting firm for fiscal 2026. Stockholders also gave advisory (non-binding) approval of the company’s executive compensation.

Key Details

• Equity plan increase: 3,550,000 shares added under Amendment No. 3 (Plan Amendment approved with 68,005,433 For; 1,269,231 Against; 41,536 Abstain; 3,918,311 Broker non-votes).
• Director elections: All nominees elected — Keith Bradley, Ph.D.; Shaundra D. Clay; Stuart M. Essig, Ph.D.; Jeffrey A. Graves, Ph.D.; Barbara B. Hill; Renee W. Lo; Christian S. Schade (individual vote totals reported in the filing).
• Auditor ratification: PwC ratified for 2026 (For: 72,313,820; Against: 863,179; Abstain: 57,512).
• Say-on-pay advisory vote: Approved (For: 68,472,769; Against: 732,580; Abstain: 110,851; Broker non-votes: 3,918,311).

Why It Matters

• The share increase gives Integra flexibility to grant future equity awards for employee and executive compensation, which supports retention and incentives but can lead to shareholder dilution if awards are issued.
• Ratification of PwC and the re-election of the full board maintain continuity in financial oversight and governance. The advisory approval of executive pay signals broad shareholder support for the company’s compensation practices.